These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 32821334)

  • 1. Ipragliflozin-induced improvement of liver steatosis in obese mice may involve sirtuin signaling.
    Suga T; Sato K; Ohyama T; Matsui S; Kobayashi T; Tojima H; Horiguchi N; Yamazaki Y; Kakizaki S; Nishikido A; Okamura T; Yamada M; Kitamura T; Uraoka T
    World J Hepatol; 2020 Jul; 12(7):350-362. PubMed ID: 32821334
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ipragliflozin Improves Hepatic Steatosis in Obese Mice and Liver Dysfunction in Type 2 Diabetic Patients Irrespective of Body Weight Reduction.
    Komiya C; Tsuchiya K; Shiba K; Miyachi Y; Furuke S; Shimazu N; Yamaguchi S; Kanno K; Ogawa Y
    PLoS One; 2016; 11(3):e0151511. PubMed ID: 26977813
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fibroblast growth factor 21 increases hepatic oxidative capacity but not physical activity or energy expenditure in hepatic peroxisome proliferator-activated receptor γ coactivator-1α-deficient mice.
    Fletcher JA; Linden MA; Sheldon RD; Meers GM; Morris EM; Butterfield A; Perfield JW; Rector RS; Thyfault JP
    Exp Physiol; 2018 Mar; 103(3):408-418. PubMed ID: 29215172
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of SGLT2 selective inhibitor ipragliflozin on hyperglycemia, hyperlipidemia, hepatic steatosis, oxidative stress, inflammation, and obesity in type 2 diabetic mice.
    Tahara A; Kurosaki E; Yokono M; Yamajuku D; Kihara R; Hayashizaki Y; Takasu T; Imamura M; Li Q; Tomiyama H; Kobayashi Y; Noda A; Sasamata M; Shibasaki M
    Eur J Pharmacol; 2013 Sep; 715(1-3):246-55. PubMed ID: 23707905
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ipragliflozin, an SGLT2 Inhibitor, Ameliorates High-Fat Diet-Induced Metabolic Changes by Upregulating Energy Expenditure through Activation of the AMPK/ SIRT1 Pathway.
    Lee JY; Lee M; Lee JY; Bae J; Shin E; Lee YH; Lee BW; Kang ES; Cha BS
    Diabetes Metab J; 2021 Nov; 45(6):921-932. PubMed ID: 33611885
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Methionine restriction prevents the progression of hepatic steatosis in leptin-deficient obese mice.
    Malloy VL; Perrone CE; Mattocks DA; Ables GP; Caliendo NS; Orentreich DS; Orentreich N
    Metabolism; 2013 Nov; 62(11):1651-61. PubMed ID: 23928105
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Protective Effects of Ipragliflozin, a Sodium-glucose Cotransporter 2 Inhibitor, on a Non-alcoholic Steatohepatitis Mouse Model.
    Yamane M; Matono T; Okano JI; Nagahara R; Matsuki Y; Okamoto T; Miyoshi KI; Sugihara T; Nagahara T; Koda M; Isomoto H
    Yonago Acta Med; 2019 Mar; 62(1):30-35. PubMed ID: 30962742
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MK-0626, a selective DPP-4 inhibitor, attenuates hepatic steatosis in ob/ob mice.
    Ohyama T; Sato K; Yamazaki Y; Hashizume H; Horiguchi N; Kakizaki S; Mori M; Kusano M; Yamada M
    World J Gastroenterol; 2014 Nov; 20(43):16227-35. PubMed ID: 25473177
    [TBL] [Abstract][Full Text] [Related]  

  • 9. LB100 ameliorates nonalcoholic fatty liver disease
    Chen XY; Cai CZ; Yu ML; Feng ZM; Zhang YW; Liu PH; Zeng H; Yu CH
    World J Gastroenterol; 2019 Dec; 25(45):6607-6618. PubMed ID: 31832001
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neohesperidin Exerts Lipid-Regulating Effects in vitro and in vivo via Fibroblast Growth Factor 21 and AMP-Activated Protein Kinase/Sirtuin Type 1/Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1α Signaling Axis.
    Wu H; Liu Y; Chen X; Zhu D; Ma J; Yan Y; Si M; Li X; Sun C; Yang B; He Q; Chen K
    Pharmacology; 2017; 100(3-4):115-126. PubMed ID: 28554169
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Astragalus polysaccharides affect insulin resistance by regulating the hepatic SIRT1-PGC-1α/PPARα-FGF21 signaling pathway in male Sprague Dawley rats undergoing catch-up growth.
    Gu C; Zeng Y; Tang Z; Wang C; He Y; Feng X; Zhou L
    Mol Med Rep; 2015 Nov; 12(5):6451-60. PubMed ID: 26323321
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of ketogenic starvation sensors in mediating the renal protective effects of SGLT2 inhibitors in type 2 diabetes.
    Packer M
    J Diabetes Complications; 2020 Sep; 34(9):107647. PubMed ID: 32534886
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PPARα-Deficient ob/ob Obese Mice Become More Obese and Manifest Severe Hepatic Steatosis Due to Decreased Fatty Acid Oxidation.
    Gao Q; Jia Y; Yang G; Zhang X; Boddu PC; Petersen B; Narsingam S; Zhu YJ; Thimmapaya B; Kanwar YS; Reddy JK
    Am J Pathol; 2015 May; 185(5):1396-408. PubMed ID: 25773177
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Short-term inhibition of peroxisome proliferator-activated receptor-gamma coactivator-1alpha expression reverses diet-induced diabetes mellitus and hepatic steatosis in mice.
    De Souza CT; Araújo EP; Prada PO; Saad MJ; Boschero AC; Velloso LA
    Diabetologia; 2005 Sep; 48(9):1860-71. PubMed ID: 16025253
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ipragliflozin, an SGLT2 inhibitor, exhibits a prophylactic effect on hepatic steatosis and fibrosis induced by choline-deficient l-amino acid-defined diet in rats.
    Hayashizaki-Someya Y; Kurosaki E; Takasu T; Mitori H; Yamazaki S; Koide K; Takakura S
    Eur J Pharmacol; 2015 May; 754():19-24. PubMed ID: 25701721
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dietary capsaicin reduces obesity-induced insulin resistance and hepatic steatosis in obese mice fed a high-fat diet.
    Kang JH; Goto T; Han IS; Kawada T; Kim YM; Yu R
    Obesity (Silver Spring); 2010 Apr; 18(4):780-7. PubMed ID: 19798065
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ethanol administration exacerbates the abnormalities in hepatic lipid oxidation in genetically obese mice.
    Everitt H; Hu M; Ajmo JM; Rogers CQ; Liang X; Zhang R; Yin H; Choi A; Bennett ES; You M
    Am J Physiol Gastrointest Liver Physiol; 2013 Jan; 304(1):G38-47. PubMed ID: 23139221
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Monascin and ankaflavin act as natural AMPK activators with PPARα agonist activity to down-regulate nonalcoholic steatohepatitis in high-fat diet-fed C57BL/6 mice.
    Hsu WH; Chen TH; Lee BH; Hsu YW; Pan TM
    Food Chem Toxicol; 2014 Feb; 64():94-103. PubMed ID: 24275089
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Sodium Glucose Cotransporter 2 Inhibitor Ipragliflozin Promotes Preferential Loss of Fat Mass in Non-obese Diabetic Goto-Kakizaki Rats.
    Takasu T; Hayashizaki Y; Hirosumi J; Minoura H; Amino N; Kurosaki E; Takakura S
    Biol Pharm Bull; 2017; 40(5):675-680. PubMed ID: 28458353
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Argan oil prevents down-regulation induced by endotoxin on liver fatty acid oxidation and gluconeogenesis and on peroxisome proliferator-activated receptor gamma coactivator-1α, (PGC-1α), peroxisome proliferator-activated receptor α (PPARα) and estrogen related receptor α (ERRα).
    El Kebbaj R; Andreoletti P; El Hajj HI; El Kharrassi Y; Vamecq J; Mandard S; Saih FE; Latruffe N; El Kebbaj MS; Lizard G; Nasser B; Cherkaoui-Malki M
    Biochim Open; 2015; 1():51-59. PubMed ID: 29632829
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.